Effectiveness of vericiguat in heart failure across ejection fraction phenotypes: a comprehensive meta-analytic trial sequential analysis and meta-regression analysis Authors: Ibrahim Khalil, M. Rafiqul Islam, Manisha Das, Sunjida Amin Promi, Sajjad Ghanim Al-Badri, Sakib Abrar, Afsana Rahman Maliha, Avijit Debnath, Md Ekramul Islam, AKM Mushfiquzzaman, Md. Imran Hossain Published: 2026 ABSTRACT Background:Heart failure (HF) remains a global health challenge, with distinct phenotypes – heart failure with reduced ejection fraction (HFrEF ≤40%) and heart failure with preserved ejection fraction (HFpEF ≥50%) – requiring tailored therapies. Vericiguat, a soluble guanylate cyclase stimulator, targets the nitric oxide -soluble guanylate cyclase-cyclic guanosine monophosphate pathway to reduce cardiac stress, showing promise in HFrEF but with unclear efficacy in HFpEF. This meta-analysis evaluates Vericiguat’s effectiveness across HF phenotypes using trial sequential analysis (TSA) and meta-regression.Methods:Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we included eight randomized controlled trials (17,381 patients) comparing Vericiguat to control in HFrEF and HFpEF patients. Outcomes assessed were hospitalization for HF, all-cause mortality, cardiovascular mortality, and the composite endpoint (cardiovascular death or first hospitalization). Random-effects models calculated pooled risk ratio (RR). TSA controlled for type I/II errors, and meta-regression explored covariates (age, sex, NT-proBNP, HF subgroup). Sensitivity analyses assessed robustness.Results:Vericiguat reduced hospitalization for HF (RR: 0.90, 95% confidence interval [CI]: 0.82–0.98, P = 0.0201) and the composite endpoint (RR: 0.88, 95% CI: 0.78–0.99, P = 0.035), but TSA indicated inconclusive evidence (required information sizes: 29,929 and 48,016 patients, respectively). No significant effect was observed for all-cause mortality (RR: 0.98, 95% CI: 0.68–1.40, P = 0.904) or cardiovascular mortality (RR: 0.91, 95% CI: 0.64–1.30, P = 0.6091). Heterogeneity was minimal (I2 = 0–17%). Meta-regression showed no significant covariate effects, though HFrEF trended toward benefit (P = 0.1329). Sensitivity analysis identified VITALITY-HFpEF as an influential outlier.Conclusions:Vericiguat modestly reduces hospitalization and composite outcomes in HF, particularly HFrEF, but lacks mortality benefits. Larger, phenotype-specific trials are needed to confirm efficacy, especially in HFpEF, to refine Vericiguat’s role in HF management. Introduction Heart failure (HF) is a pressing global health crisis, affecting an estimated 64 million individuals worldwide and contributing to substantial morbidity, mortality, and economic burden[1]. Characterized by the heart’s inability to pump blood effectively to meet the body’s demands, HF manifests in two primary phenotypes: heart failure with reduced ejection fraction (HFrEF), where the left ventricular ejection fraction (LVEF) is ≤40%, and heart failure with preserved ejection fraction (HFpEF), where LVEF is ≥50%[2]. These phenotypes differ significantly in their pathophysiology, with HFrEF often linked to systolic dysfunction and HFpEF associated with diastolic dysfunction, increased ventricular stiffness, and systemic inflammation[3]. Risk stratification tools, such as GRACE and TIMI scores, which are well validated in conditions like acute coronary syndromes (including STEMI) that often precede HF, play a crucial role in identifying high-risk patients and guiding tailored therapies to mitigate progression and adverse outcomes[4]. The clinical management of HF has evolved over the past few decades, with cornerstone therapies such as beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor-neprilysin inhibitors (ARNIs), and sodium-glucose cotransporter-2 (SGLT2) inhibitors demonstrating significant reductions in morbidity and mortality, particularly in HFrEF[5]. However, HFpEF remains a therapeutic challenge, with fewer evidence-based treatments available, leading to persistently high rates of hospitalization and poor quality of life[6]. Despite these advances, a substantial proportion of HF patients across both phenotypes continue to experience adverse outcomes, including frequent hospitalizations, cardiovascular mortality, and all-cause mortality, underscoring the urgent need for novel therapeutic strategies to address unmet clinical needs[7]. Vericiguat, a soluble guanylate cyclase (sGC) stimulator, represents a promising advancement in HF management by targeting the nitric oxide (NO)-sGC-cyclic guanosine monophosphate (cGMP) pathway, which is often impaired in HF due to endothelial dysfunction and oxidative stress[8]. By enhancing cGMP production, Vericiguat promotes vasodilation, reduces cardiac preload and afterload, and mitigates myocardial stress, potentially offering benefits across the HF spectrum[9]. The landmark VICTORIA trial demonstrated Vericiguat’s efficacy in HFrEF, showing a significant reduction in the composite endpoint of cardiovascular death or first hospitalization for HF (hazard ratio: 0.90, 95% CI: 0.82–0.98, P = 0.02) in high-risk patients[10]. However, its role in HFpEF remains less defined, with trials like SOCRATES-PRESERVED and VITALITY-HFpEF yielding inconclusive results on functional outcomes, highlighting the need for a broader evaluation of Vericiguat’s effectiveness across ejection fraction phenotypes[11]. Moreover, while Vericiguat’s impact on composite outcomes is promising, its effects on specific endpoints such as all-cause mortality, cardiovascular mortality, and hospitalization for HF require further scrutiny, particularly in diverse patient populations with varying baseline characteristics and comorbidities[12]. Previous meta-analyses on Vericiguat have provided valuable insights but are limited by small sample sizes, a lack of robust statistical adjustments for heterogeneity, and a failure to assess the reliability of cumulative evidence[13]. For instance, a 2023 meta-analysis by Yang et al. pooled only four randomized controlled trials (RCTs), resulting in wide confidence intervals (e.g., risk ratio [RR] for all-cause mortality: 0.97, 95% CI: 0.87–1.08) and unadjusted heterogeneity (I2 up to 96%), without trial sequential analysis (TSA) or meta-regression to evaluate evidence strength or covariate influences[14]. To address these gaps, this systematic review and meta-analysis employs advanced statistical methodologies, including TSA and meta-regression, to evaluate Vericiguat’s effectiveness across HFrEF and HFpEF. TSA, a method never previously applied to Vericiguat studies, adjusts for type I and type II errors in cumulative meta-analyses by applying O’Brien-Fleming alpha-spending boundaries, ensuring that conclusions are not drawn prematurely due to insufficient sample sizes[15]. This approach is critical given the variable trial sizes in Vericiguat research (ranging from 6678 to 17,381 patients for different outcomes) and the need to determine whether the required information size has been met to confirm or refute Vericiguat’s effects on outcomes like cardiovascular mortality and hospitalization[16]. Additionally, meta-regression is utilized to explore the influence of covariates such as age, sex, NT-proBNP levels, population size, and HF subgroup (HFrEF vs. HFpEF) on treatment outcomes, an analysis not previously conducted in this context[17]. This allows for a nuanced understanding of heterogeneity and potential effect modifiers, addressing questions unanswered by prior studies, such as whether Vericiguat’s benefits vary by ejection fraction phenotype or biomarker levels. Furthermore, advanced sensitivity analyses, including influence diagnostics and sensitivity analyses, are employed to assess the robustness of findings, providing a level of statistical rigor previously unexplored in Vericiguat research[18]. By focusing on key outcomes – hospitalization for HF, all-cause mortality, cardiovascular mortality, and the composite endpoint of cardiovascular death or first hospitalization – this study aims to deliver a comprehensive, evidence-based assessment of Vericiguat’s role in HF management, offering actionable insights for clinicians and researchers to optimize patient care across diverse HF phenotypes.HIGHLIGHTSVericiguat cut hospitalization risk: risk ratio (RR) 0.90, 95% confidence interval 0.82–0.98.Composite outcome improved with vericiguat: RR 0.88, P = 0.035.No mortality benefit seen: all-cause RR 0.98, cardiovascular RR 0.91.Trial sequential analysis showed inconclusive results; more trials are needed for heart failure with preserved ejection fraction.Meta-regression: heart failure with reduced ejection fraction trended toward benefit, P = 0.1329. HIGHLIGHTS Vericiguat cut hospitalization risk: risk ratio (RR) 0.90, 95% confidence interval 0.82–0.98. Vericiguat cut hospitalization risk: risk ratio (RR) 0.90, 95% confidence interval 0.82–0.98. Composite outcome improved with vericiguat: RR 0.88, P = 0.035. Composite outcome improved with vericiguat: RR 0.88, P = 0.035. No mortality benefit seen: all-cause RR 0.98, cardiovascular RR 0.91. No mortality benefit seen: all-cause RR 0.98, cardiovascular RR 0.91. Trial sequential analysis showed inconclusive results; more trials are needed for heart failure with preserved ejection fraction. Trial sequential analysis showed inconclusive results; more trials are needed for heart failure with preserved ejection fraction. Meta-regression: heart failure with reduced ejection fraction trended toward benefit, P = 0.1329. Meta-regression: heart failure with reduced ejection fraction trended toward benefit, P = 0.1329. Methods Study design This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and was registered with the PROSPERO database (registration ID: CRD42024590748)[19]. The study also adhered to the Assessing the Methodological Quality of Systematic Reviews guidelines to ensure methodological rigor and transparency[20]. The primary objective was to evaluate the effectiveness of Vericiguat in adult patients with HFrEF or HFpEF by synthesizing evidence from RCTs, focusing on key clinical outcomes: hospitalization for HF, all-cause mortality, cardiovascular mortality, and the primary composite outcome of death from cardiovascular causes or first hospitalization for HF. To address limitations in prior research, TSA was employed to control for type I and type II errors and to determine the reliability of cumulative evidence, while meta-regression and advanced sensitivity analyses were conducted to explore covariate effects and ensure robustness, representing novel statistical approaches in Vericiguat research[21]. Eligibility criteria Eligible studies were RCTs evaluating Vericiguat in adults aged 18 years or older with a confirmed diagnosis of HFrEF (ejection fraction ≤40%) or HFpEF (ejection fraction ≥50%), as defined by current clinical guidelines[22]. Studies were required to compare Vericiguat, administered alongside standard care, against a control group receiving placebo or standard care alone, and to report at least one of the specified outcomes: hospitalization for HF, all-cause mortality, cardiovascular mortality, or the composite endpoint. Inclusion was restricted to full-text articles published in English in peer-reviewed journals up to 1 May 2025. Excluded were non-randomized studies, case reports, editorials, reviews, pediatric trials, studies with unclear HF definitions, those combining Vericiguat with other experimental therapies, investigations of non-HF conditions, and publications lacking sufficient outcome data or available only as abstracts or conference proceedings[19]. Search strategy A systematic literature search was conducted across PubMed, Scopus, Web of Science, and ClinicalTrials.gov, covering studies from database inception to 1 May 2025. The search strategy combined keywords and controlled vocabulary terms, including “Vericiguat,” “heart failure,” “HFrEF,” “HFpEF,” “mortality,” and “hospitalization,” linked with Boolean operators and truncations to optimize retrieval of relevant RCTs[19]. Reference lists of included studies and relevant reviews were manually searched, and clinical experts were consulted to identify unpublished or ongoing trials, ensuring a comprehensive evidence base[23]. The full electronic search strategy, including keywords (“Vericiguat” OR “sGC stimulator”), Boolean operators (AND, OR), and date ranges, is provided in Supplemental Digital Content Appendix 1, available at: http://links.lww.com/MS9/B249. Study selection Two independent reviewers screened titles and abstracts against the eligibility criteria to identify RCTs evaluating Vericiguat in HFrEF or HFpEF populations. Full-text articles were retrieved and assessed, resulting in the inclusion of eight RCTs. Discrepancies between reviewers were resolved through discussion or consultation with a third reviewer, ensuring a rigorous and unbiased selection process consistent with systematic review best practices[19]. Data extraction Data were extracted independently by two reviewers using a standardized form, capturing study characteristics (design, sample size, publication year), participant demographics (age, sex, HF subtype), intervention details (Vericiguat dosage, duration), comparator details (placebo or standard care), and outcome data (hospitalization for HF, all-cause mortality, cardiovascular mortality, and the composite endpoint). Discrepancies were resolved through consensus or third-party adjudication, ensuring accuracy and consistency[19]. Risk of bias assessment The methodological quality of the included RCTs was assessed using the Cochrane Risk of Bias Tool 2, evaluating five domains: randomization process, deviations from intended interventions, missing outcome data, outcome measurement, and selective reporting[24]. Each domain was rated as low risk, high risk, or some concerns, with results summarized to provide insight into potential biases affecting the reliability of the meta-analysis findings[24]. Data synthesis Data synthesis was performed using a random-effects model to account for potential heterogeneity across studies, with effect sizes expressed as RR and 95% CIs for the outcomes of hospitalization for HF, all-cause mortality, cardiovascular mortality, and the composite endpoint. Analyses were conducted using R (version 4.4.1) and Python (version 3.12), with forest plots generated to visualize pooled estimates[25]. Heterogeneity was assessed using Cochran’s Q test and the I2 statistic, with I2 values interpreted to evaluate variability across studies, ensuring a robust synthesis that addressed differences in study populations and designs[26]. To address potential small-study effects and publication bias, a funnel plot was visualized for the relevant outcome. Trial sequential analysis TSA was conducted to assess the reliability of the meta-analysis findings for each outcome, a novel approach in Vericiguat research to control for type I and type II errors. TSA applied a 5% symmetric O’Brien-Fleming alpha-spending boundary (type I error: 5.0%, power: 80.0%, variance-based heterogeneity correction) with sample size as the information axis. A low bias-based relative risk reduction estimate was used, except for cardiovascular mortality, where a user-defined relative risk reduction of 23.0% was applied. TSA evaluated whether the cumulative Z-curve crossed the conventional 5% threshold or O’Brien-Fleming boundaries, determining if the required information size was met to confirm or refute Vericiguat’s effect on each outcome, addressing a gap in prior studies that lacked such rigorous cumulative evidence assessment[21]. Zero-event studies were excluded from TSA and forest plots to avoid bias in relative risk estimation, as constant continuity corrections could inflate effects in sparse data scenarios; this approach aligns with recommendations for conservative analysis in low-event settings[26]. Sensitivity analysis Advanced sensitivity analyses were conducted to evaluate the robustness of the meta-analysis and meta-regression findings, employing methods not previously applied in Vericiguat research. This included influence diagnostics to identify outliers and assess the impact of individual studies on pooled estimates, as well as funnel plots to examine publication bias. These methods ensured the stability of the results, addressing potential biases or undue influence from specific studies, thereby enhancing the validity of the conclusions with a level of statistical rigor unprecedented in this field[26]. Meta-regression analysis Meta-regression was performed to explore the influence of covariates (age, population, sex, NT-proBNP, and subgroup [HFrEF vs. HFpEF]) on Vericiguat’s effectiveness across the specified outcomes, with results summarized in Table 2. The five models were constructed in a stepwise, hypothesis-driven manner: Model 1 included core demographics and HF subgroup to establish baseline effects; model 2 added the key prognostic biomarker NT-proBNP; models 3–5 incorporated biologically plausible interaction terms (e.g., age × NT-proBNP for potential synergistic effects on disease progression, sex × NT-proBNP given sex differences in natriuretic peptide biology, and population × NT-proBNP as a proxy for study-level power) to explore effect modification, following established approaches in HF meta-regression. This strategy balances exploration with avoidance of overfitting, given limited covariate data[27]. Results Baseline characteristics of included studies The baseline characteristics of the included studies in this meta-analysis reveal a diverse cohort of HF patients across HFrEF and HFpEF phenotypes, with a total of eight studies representing 17,381 patients (Fig. 1, Table 1). The studies, spanning from 2015 to 2023, included populations ranging from 419 to 5050 participants, with mean ages between 67.3 and 73 years. Notably, HFrEF trials, such as those by P. W. Armstrong et al. (2020, 2022), Adriaan A. Voors et al. (2021), Mihai Gheorghiade et al. (2015), and Burkert Pieske et al. (2023), reported a lower proportion of female participants, ranging from 19.7 to 24.1%, reflecting the typical demographic distribution in HFrEF cohorts. In contrast, HFpEF studies, including those by Gerasimos Filippatos et al. (2017), Paul W. Armstrong et al. (VITALITY-HFpEF 2020), and Burkert Pieske et al. (2017), showed a higher female representation, with percentages ranging from 46.6 to 49%, consistent with the known epidemiology of HFpEF. This variability in age and sex distribution across the studies underscores the importance of considering demographic factors in evaluating Vericiguat’s effectiveness across different HF phenotypes. Treatment with Vericiguat in the included studies typically involved oral administration at doses of 2.5, 5, or 10 mg once daily, titrated based on tolerability and blood pressure; the duration ranged from 12 weeks to 24 months, with frequency adjusted for renal function if needed. Figure 1.PRISMA 2020 flow diagram for systematic reviews, which includes searches of databases and registers. Table 1Population baseline characteristics of included studies.StudyGroupTotal populationMean age (years)P. W. Armstrong et al. 2020HFrEF505067.3Gerasimos Filippatos et al. 2017HFpEF42973Paul W. Armstrong et al. 2020 (VITALITY-HFpEF 2020)HFpEF78972.7Burkert Pieske et al. 2017HFpEF47773Mihai Gheorghiad et al. 2015HFrEF45668Burkert Pieske et al. 2023HFrEF41967.3Paul W. Armstrong et al. 2022HFrEF480568Adriaan A. Voors et al. 2021HFrEF495669 PRISMA 2020 flow diagram for systematic reviews, which includes searches of databases and registers. Table 1Population baseline characteristics of included studies.StudyGroupTotal populationMean age (years)P. W. Armstrong et al. 2020HFrEF505067.3Gerasimos Filippatos et al. 2017HFpEF42973Paul W. Armstrong et al. 2020 (VITALITY-HFpEF 2020)HFpEF78972.7Burkert Pieske et al. 2017HFpEF47773Mihai Gheorghiad et al. 2015HFrEF45668Burkert Pieske et al. 2023HFrEF41967.3Paul W. Armstrong et al. 2022HFrEF480568Adriaan A. Voors et al. 2021HFrEF495669 Population baseline characteristics of included studies. Hospitalization for HF For the outcome of hospitalization for HF, the TSA included six trials, with a cumulative sample size of 16,866 patients, evaluating vericiguat versus control (Fig. 2: Forest plot of hospitalization outcomes; Fig. 3: TSA curve for hospitalization). The pooled RR was 0.90 (95% CI: 0.82–0.98, P = 0.0201), favoring vericiguat, based on a random-effects model with constant continuity correction (shared value: 0.5) for zero-event trials, which were excluded. Heterogeneity was minimal (Q = 1.28, P = 0.9366; I2 = 0.0%; D2 = 0.83). The TSA applied a 5% symmetric O’Brien-Fleming alpha-spending boundary (type I error: 5.0%, power: 80.0%, variance-based heterogeneity correction) with sample size as the information axis and a low-bias-based relative risk reduction estimate. The cumulative Z-curve, while initially crossing the conventional 5% threshold favoring vericiguat, ultimately approached the null (Z = 0) and did not cross the O’Brien-Fleming boundaries after 16,866 patients, falling short of the required information size of 29,929 patients (Fig. 3). This suggests that the apparent benefit of vericiguat in reducing hospitalization risk may be inconclusive, highlighting the need for further trials to confirm its efficacy across HF patients with preserved and reduced ejection fraction phenotypes. Figure 2.Forest plot illustrating the effectiveness of vericiguat compared to control in heart failure across ejection fraction phenotypes. This forest plot visualizes the pooled RR with 95% confidence intervals (CI) for key outcomes – hospitalization for heart failure, all-cause mortality, cardiovascular mortality, and the primary composite outcome (death from cardiovascular causes or first hospitalization) – derived from a meta-analysis of randomized controlled trials. Additional statistical metrics, including sample size (N), P-value, Q statistic, I2 (heterogeneity), and D2, are annotated for each outcome, highlighting the robustness and variability of the results across HFrEF and HFpEF patients. Figure 3.(A) Trial sequential analysis of vericiguat versus control for hospitalization for heart failure, showing the cumulative Z-curve (blue) with conventional 5% thresholds (purple dashed lines) and 5% symmetric O’Brien-Fleming boundaries (red lines) across six trials (cumulative sample size: 16,866; required information size: 29,929). (B) Simplified trial sequential analysis of vericiguat versus control for hospitalization for heart failure, focusing on the cumulative Z-curve and 5% symmetric O’Brien-Fleming boundaries (red lines) with a cumulative sample size of 16,866 patients, compared to the required information size of 29,929. (C) Trial sequential analysis of vericiguat versus control for all-cause mortality, depicting the cumulative Z-curve (blue) with conventional 5% thresholds and 5% symmetric O’Brien-Fleming boundaries (red lines) across six trials (cumulative sample size: 6678). (D) Simplified trial sequential analysis of vericiguat versus control for all-cause mortality, highlighting the cumulative Z-curve (blue) and 5% symmetric O’Brien-Fleming boundaries (red lines) with a cumulative sample size of 6678 patients. Forest plot illustrating the effectiveness of vericiguat compared to control in heart failure across ejection fraction phenotypes. This forest plot visualizes the pooled RR with 95% confidence intervals (CI) for key outcomes – hospitalization for heart failure, all-cause mortality, cardiovascular mortality, and the primary composite outcome (death from cardiovascular causes or first hospitalization) – derived from a meta-analysis of randomized controlled trials. Additional statistical metrics, including sample size (N), P-value, Q statistic, I2 (heterogeneity), and D2, are annotated for each outcome, highlighting the robustness and variability of the results across HFrEF and HFpEF patients. (A) Trial sequential analysis of vericiguat versus control for hospitalization for heart failure, showing the cumulative Z-curve (blue) with conventional 5% thresholds (purple dashed lines) and 5% symmetric O’Brien-Fleming boundaries (red lines) across six trials (cumulative sample size: 16,866; required information size: 29,929). (B) Simplified trial sequential analysis of vericiguat versus control for hospitalization for heart failure, focusing on the cumulative Z-curve and 5% symmetric O’Brien-Fleming boundaries (red lines) with a cumulative sample size of 16,866 patients, compared to the required information size of 29,929. (C) Trial sequential analysis of vericiguat versus control for all-cause mortality, depicting the cumulative Z-curve (blue) with conventional 5% thresholds and 5% symmetric O’Brien-Fleming boundaries (red lines) across six trials (cumulative sample size: 6678). (D) Simplified trial sequential analysis of vericiguat versus control for all-cause mortality, highlighting the cumulative Z-curve (blue) and 5% symmetric O’Brien-Fleming boundaries (red lines) with a cumulative sample size of 6678 patients. All-cause mortality For the outcome of death from any cause, the TSA included six trials with a cumulative sample size of 6678 patients, evaluating vericiguat versus control. The pooled RR was 0.98 (95% CI: 0.68–1.40, P = 0.904), based on a random-effects model with constant continuity correction (shared value: 1.0) for zero-event trials, which were excluded. Heterogeneity was low (Q = 4.32, P = 0.5046; I2 = 0.0%; D2 = 0.96). The TSA utilized a 5% symmetric O’Brien-Fleming alpha-spending boundary (type I error: 5.0%, power: 80.0%, variance-based heterogeneity correction) with sample size as the information axis and a low-bias-based relative risk reduction estimate. The cumulative Z-curve remained near the null (Z = 0) throughout, not crossing the conventional 5% threshold or the O’Brien-Fleming boundaries after 6678 patients, indicating no significant effect of vericiguat on all-cause mortality (Fig. 2: Forest plot of all-cause mortality; Fig. 3: TSA curve for all-cause mortality). These findings suggest that vericiguat does not substantially alter mortality risk across HF patients with preserved and reduced ejection fraction phenotypes, underscoring the need for further investigation. Cardiovascular mortality For the outcome of death from cardiovascular causes, the TSA included six trials with a cumulative sample size of 17,179 patients, evaluating vericiguat versus control (Fig. 2: Forest plot of CV mortality; Fig. 4: TSA curve for CV mortality). The pooled RR was 0.91 (95% CI: 0.64–1.30, P = 0.6091), based on a random-effects model with constant continuity correction (shared value: 1.0) for zero-event trials, which were excluded. Heterogeneity was low (Q = 6.03, P = 0.3029; I2 = 17.0%; D2 = 0.98). The TSA applied a 5% symmetric O’Brien-Fleming alpha-spending boundary (type I error: 5.0%, power: 80.0%, variance-based heterogeneity correction) with sample size as the information axis and a user-defined relative risk reduction of 23.0%. The cumulative Z-curve remained near the null (Z = 0) throughout, not crossing the conventional 5% threshold or the O’Brien-Fleming boundaries after 17,179 patients, falling short of the required information size of 184,229 patients (Fig. 4). These findings indicate no significant effect of vericiguat on cardiovascular mortality in HF patients across preserved and reduced ejection fraction phenotypes, suggesting the need for additional trials to achieve conclusive evidence. Figure 4.(A) Trial sequential analysis of vericiguat versus control for cardiovascular mortality, showing the cumulative Z-curve (blue) with conventional 5% thresholds (purple dashed lines) and 5% symmetric O’Brien-Fleming boundaries (red lines) across six trials (cumulative sample size: 17,179; required information size: 18,4229). (B) Simplified trial sequential analysis of vericiguat versus control for cardiovascular mortality, highlighting the cumulative Z-curve (blue) and 5% symmetric O’Brien-Fleming boundaries (red lines) with a cumulative sample size of 17,179 patients, compared to the required information size of 184,229. (C) Trial sequential analysis of vericiguat versus control for the primary composite outcome (death from cardiovascular causes or first hospitalization for heart failure), depicting the cumulative Z-curve (blue) with conventional 5% thresholds (purple dashed lines) and 5% symmetric O’Brien-Fleming boundaries (red lines) across five trials (cumulative sample size: 16,685; required information size: 48,016). (D) Simplified trial sequential analysis of vericiguat versus control for the primary composite outcome (death from cardiovascular causes or first hospitalization for heart failure), focusing on the cumulative Z-curve (blue) and 5% symmetric O’Brien-Fleming boundaries (red lines) with a cumulative sample size of 16,685 patients, compared to the required information size of 48,016. (A) Trial sequential analysis of vericiguat versus control for cardiovascular mortality, showing the cumulative Z-curve (blue) with conventional 5% thresholds (purple dashed lines) and 5% symmetric O’Brien-Fleming boundaries (red lines) across six trials (cumulative sample size: 17,179; required information size: 18,4229). (B) Simplified trial sequential analysis of vericiguat versus control for cardiovascular mortality, highlighting the cumulative Z-curve (blue) and 5% symmetric O’Brien-Fleming boundaries (red lines) with a cumulative sample size of 17,179 patients, compared to the required information size of 184,229. (C) Trial sequential analysis of vericiguat versus control for the primary composite outcome (death from cardiovascular causes or first hospitalization for heart failure), depicting the cumulative Z-curve (blue) with conventional 5% thresholds (purple dashed lines) and 5% symmetric O’Brien-Fleming boundaries (red lines) across five trials (cumulative sample size: 16,685; required information size: 48,016). (D) Simplified trial sequential analysis of vericiguat versus control for the primary composite outcome (death from cardiovascular causes or first hospitalization for heart failure), focusing on the cumulative Z-curve (blue) and 5% symmetric O’Brien-Fleming boundaries (red lines) with a cumulative sample size of 16,685 patients, compared to the required information size of 48,016. Primary composite outcome (death from cardiovascular causes or first hospitalization for HF) For the primary composite outcome of death from cardiovascular causes or first hospitalization for HF, the TSA included five trials, with a cumulative sample size of 16,685 patients, evaluating vericiguat versus control. The pooled RR was 0.88 (95% CI: 0.78–0.99, P = 0.035) based on a random-effects model with constant continuity correction (shared value: 0.5) for zero-event trials, which were excluded (Fig. 2: Forest plot of composite outcome; Fig. 4: TSA curve for composite outcome). Heterogeneity was minimal (Q = 2.55, P = 0.6353; I2 = 0.0%; D2 = 0.9). The TSA applied a 5% symmetric O’Brien-Fleming alpha-spending boundary (type I error: 5.0%, power: 80.0%, variance-based heterogeneity correction) with sample size as the information axis and a low-bias-based relative risk reduction estimate. The cumulative Z-curve initially crossed the conventional 5% threshold favoring vericiguat, peaked above 2, and then declined toward the null (Z = 0) after 16,685 patients, not crossing the O’Brien-Fleming boundaries and falling short of the required information size of 48,016 patients (Fig. 4). These results suggest a potential modest benefit of vericiguat on the composite outcome in HF patients across preserved and reduced ejection fraction phenotypes, though further trials are needed for definitive confirmation. Sensitivity analysis in HFrEF To evaluate the robustness of the findings and address the potential influence from HFpEF trials, particularly the neutral VITALITY-HFpEF study, which enrolled patients with preserved ejection fraction (LVEF ≥45%) and showed no significant improvement in primary functional endpoints or clear signals on hard clinical outcomes, a dedicated sensitivity analysis was conducted, restricting the dataset to studies or subgroups explicitly in patients with HFrEF (LVEF ≤40%). This approach excluded HFpEF-predominant trials and focused on HFrEF data from key studies, including the large VICTORIA trial (Armstrong et al., 2020, and follow-up analyses in 2022), SOCRATES-REDUCED subsets (Gheorghiade et al., 2015), and other HFrEF-focused RCTs (Pieske et al., 2023; Voors et al., 2021). In this HFrEF-restricted analysis (Fig. 5), vericiguat demonstrated consistent and statistically significant benefits across all evaluated outcomes under the random-effects model, with low heterogeneity (I2 = 0% across panels). Specifically: Primary composite outcome (cardiovascular death or HF hospitalization): The pooled random-effects risk ratio was 0.90 (95% CI: 0.85–0.96), indicating a significant 10% relative risk reduction favoring vericiguat (Fig. 5A). This aligns closely with the landmark VICTORIA trial results and suggests greater certainty of benefit in the HFrEF phenotype compared to the mixed-phenotype primary analysis. All-cause mortality: The pooled random-effects RR was 0.93 (95% CI: 0.87–1.00; Fig. 5B), showing a trend toward reduction that approached nominal statistical significance (upper CI limit touching 1.00), representing an improvement over the neutral overall pooled estimate (RR 0.98, 95% CI: 0.68–1.40).Cardiovascular mortality: A significant benefit was observed with random-effects RR 0.91 (95% CI: 0.85–0.98; Fig. 5C), confirming a 9% relative risk reduction in this hard endpoint within HFrEF cohorts.Hospitalization for HF: The pooled random-effects RR was 0.91 (95% CI: 0.88–0.94; Fig. 5D), demonstrating a clear and consistent reduction in HF hospitalization risk. Figure 5.Forest plots from the sensitivity analysis evaluating the effectiveness of vericiguat versus placebo in heart failure with reduced ejection fraction phenotype. (A) Primary composite outcome, showing a significant risk reduction (random-effects RR 0.90, 95% CI 0.85–0.96). (B) All-cause mortality (random-effects RR 0.93, 95% CI 0.87–1.00). (C) Cardiovascular mortality (random-effects RR 0.91, 95% CI 0.85–0.98). *-(D) Hospitalization for heart failure (random-effects RR 0.91, 95% CI 0.88–0.94). Primary composite outcome (cardiovascular death or HF hospitalization): The pooled random-effects risk ratio was 0.90 (95% CI: 0.85–0.96), indicating a significant 10% relative risk reduction favoring vericiguat (Fig. 5A). This aligns closely with the landmark VICTORIA trial results and suggests greater certainty of benefit in the HFrEF phenotype compared to the mixed-phenotype primary analysis. Primary composite outcome (cardiovascular death or HF hospitalization): The pooled random-effects risk ratio was 0.90 (95% CI: 0.85–0.96), indicating a significant 10% relative risk reduction favoring vericiguat (Fig. 5A). This aligns closely with the landmark VICTORIA trial results and suggests greater certainty of benefit in the HFrEF phenotype compared to the mixed-phenotype primary analysis. All-cause mortality: The pooled random-effects RR was 0.93 (95% CI: 0.87–1.00; Fig. 5B), showing a trend toward reduction that approached nominal statistical significance (upper CI limit touching 1.00), representing an improvement over the neutral overall pooled estimate (RR 0.98, 95% CI: 0.68–1.40). All-cause mortality: The pooled random-effects RR was 0.93 (95% CI: 0.87–1.00; Fig. 5B), showing a trend toward reduction that approached nominal statistical significance (upper CI limit touching 1.00), representing an improvement over the neutral overall pooled estimate (RR 0.98, 95% CI: 0.68–1.40). Cardiovascular mortality: A significant benefit was observed with random-effects RR 0.91 (95% CI: 0.85–0.98; Fig. 5C), confirming a 9% relative risk reduction in this hard endpoint within HFrEF cohorts. Cardiovascular mortality: A significant benefit was observed with random-effects RR 0.91 (95% CI: 0.85–0.98; Fig. 5C), confirming a 9% relative risk reduction in this hard endpoint within HFrEF cohorts. Hospitalization for HF: The pooled random-effects RR was 0.91 (95% CI: 0.88–0.94; Fig. 5D), demonstrating a clear and consistent reduction in HF hospitalization risk. Hospitalization for HF: The pooled random-effects RR was 0.91 (95% CI: 0.88–0.94; Fig. 5D), demonstrating a clear and consistent reduction in HF hospitalization risk. Forest plots from the sensitivity analysis evaluating the effectiveness of vericiguat versus placebo in heart failure with reduced ejection fraction phenotype. (A) Primary composite outcome, showing a significant risk reduction (random-effects RR 0.90, 95% CI 0.85–0.96). (B) All-cause mortality (random-effects RR 0.93, 95% CI 0.87–1.00). (C) Cardiovascular mortality (random-effects RR 0.91, 95% CI 0.85–0.98). *-(D) Hospitalization for heart failure (random-effects RR 0.91, 95% CI 0.88–0.94). These results indicate that vericiguat’s efficacy is more pronounced and robust in the HFrEF phenotype, where the majority of high-quality evidence originates (particularly from the adequately powered VICTORIA trial). The attenuation or neutrality observed in the primary overall analysis likely stems from the inclusion of HFpEF data, where trials such as VITALITY-HFpEF contributed limited or absent benefit on clinical endpoints and exerted influential weighting in some pooled estimates. This sensitivity analysis strengthens confidence in vericiguat as an adjunct therapy in HFrEF to reduce hospitalizations and mortality risks, while reinforcing the need for larger, dedicated HFpEF trials to clarify its role (or lack thereof) in preserved ejection fraction populations. Sensitivity analysis: Influence diagnostics of the meta-regression model A sensitivity analysis was conducted to assess the influence of individual studies on the meta-regression model evaluating vericiguat’s effectiveness in HF across ejection fraction phenotypes, with influence diagnostics presented in Table 2 and Figure 6 (influence diagnostics plot). The VITALITY-HFpEF 2020 trial exerted the greatest influence, with a standardized residual (rstudent) of 3.1048, a DFFITS value of 0.9855, a Cook’s distance of 0.5938, and a notably low covariance ratio (cov.r) of 0.1904, indicating potential outlier status; its removal reduced the residual heterogeneity (tau2.del) to 0 and the Q statistic for heterogeneity (QE.del) to 1.9794. In contrast, other studies, such as P. W. Armstrong et al. (2022) and B. Pieske et al. (2023), showed moderate influence, with rstudent values of −0.5967 and −0.934, DFFITS of −0.3953 and −0.148, and Cook’s distances of 0.2865 and 0.022, respectively, suggesting limited impact on the overall model. The hat values and weights further highlighted the VITALITY-HFpEF trial’s leverage (hat: 0.1221, weight: 12.2124) compared to others, like B. Pieske et al. (2023) (hat: 0.0155, weight: 1.5496). The DFBETA values indicated that VITALITY-HFpEF had the largest effect on regression coefficients (dfbs: 1.7991), while others had minimal impact (e.g., P. W. Armstrong et al. 2020, dfbs: −0.103). These findings suggest that while the VITALITY-HFpEF trial significantly influenced the meta-regression, the overall model remained robust, supporting the reliability of vericiguat’s assessed effects across HF phenotypes, though caution is warranted in interpreting results driven by influential studies. The risk of bias in included studies is shown in Figure 7. The funnel plot did not show significant publication bias (Fig. 8). Figure 6.(A) Residual influence diagnostics from the meta-regression model for vericiguat in heart failure, displaying residual standard deviation (rstudent), Cook’s distance (cook.D), covariance ratio (cov.R), tau-squared influence (tau2.Del), Q statistic influence (Q.Del), hat values (hat), and weight influence (weight) across included studies, assessing model fit and influence. (B) Regression coefficients in the meta-regression model for vericiguat in heart failure, showing the coefficient values for intercept, age, population, sex, and subgroup (HFpEF vs. HFrEF), with bars indicating the magnitude and direction of the effect on the outcome. (C) Bubble plot of the meta-regression for vericiguat in heart failure, illustrating the effect size (log odds ratios) against predicted values (fitted), with bubble size representing study weight, highlighting the relationship between covariates and outcomes across preserved and reduced ejection fraction phenotypes. Figure 7.Risk of bias assessment across included studies using the Cochrane Risk of Bias Tool 2 (RoB 2). Figure 8.Funnel plot for assessing publication bias. Funnel plot with trim-and-fill adjustment evaluating publication bias across studies, plotting the standard error against the effect size (log odds ratio), with a symmetrical distribution indicating no significant publication bias, despite there being fewer than 10 studies. Table 2Table showing residual influence diagnostics data of sensitivity analysis for primary outcome (hospitalization for heart failure).StudyR studentdffitscook.dcov.rtau2.delQE.delR hatweightdfbsP. W. Armstrong et al. 2022−0.5967−0.39530.28652.22040.01139.97720.2727.0014−0.4138Adriaan Voors et al. 2021−0.3042−0.23160.11872.57740.013711.55620.271827.1773−0.2462B. Pieske et al. 2023−0.934−0.1480.0221.10820.006410.83380.01551.5496−0.1422Mihai Gheorghiade et al. 2015−0.5053−0.23850.06391.51490.008811.45170.0717.0965−0.2149VITALITY-HFpEF 20203.10480.98550.59380.190401.97940.122112.21241.7991P. W. Armstrong et al. 2020−0.0521−0.09880.02162.64420.014411.25670.249624.9629−0.103 (A) Residual influence diagnostics from the meta-regression model for vericiguat in heart failure, displaying residual standard deviation (rstudent), Cook’s distance (cook.D), covariance ratio (cov.R), tau-squared influence (tau2.Del), Q statistic influence (Q.Del), hat values (hat), and weight influence (weight) across included studies, assessing model fit and influence. (B) Regression coefficients in the meta-regression model for vericiguat in heart failure, showing the coefficient values for intercept, age, population, sex, and subgroup (HFpEF vs. HFrEF), with bars indicating the magnitude and direction of the effect on the outcome. (C) Bubble plot of the meta-regression for vericiguat in heart failure, illustrating the effect size (log odds ratios) against predicted values (fitted), with bubble size representing study weight, highlighting the relationship between covariates and outcomes across preserved and reduced ejection fraction phenotypes. Risk of bias assessment across included studies using the Cochrane Risk of Bias Tool 2 (RoB 2). Funnel plot for assessing publication bias. Funnel plot with trim-and-fill adjustment evaluating publication bias across studies, plotting the standard error against the effect size (log odds ratio), with a symmetrical distribution indicating no significant publication bias, despite there being fewer than 10 studies. Table 2Table showing residual influence diagnostics data of sensitivity analysis for primary outcome (hospitalization for heart failure).StudyR studentdffitscook.dcov.rtau2.delQE.delR hatweightdfbsP. W. Armstrong et al. 2022−0.5967−0.39530.28652.22040.01139.97720.2727.0014−0.4138Adriaan Voors et al. 2021−0.3042−0.23160.11872.57740.013711.55620.271827.1773−0.2462B. Pieske et al. 2023−0.934−0.1480.0221.10820.006410.83380.01551.5496−0.1422Mihai Gheorghiade et al. 2015−0.5053−0.23850.06391.51490.008811.45170.0717.0965−0.2149VITALITY-HFpEF 20203.10480.98550.59380.190401.97940.122112.21241.7991P. W. Armstrong et al. 2020−0.0521−0.09880.02162.64420.014411.25670.249624.9629−0.103 Table showing residual influence diagnostics data of sensitivity analysis for primary outcome (hospitalization for heart failure). Meta-regression The meta-regression analysis evaluated the effectiveness of vericiguat in HF across five models, with results summarized in Table 3 and illustrated in Figure 6B (regression coefficients plot) Figure 6C (bubble plot of effect sizes). Model 1, incorporating age, population, sex (female percentage), and subgroup (HFrEF), showed a non-significant intercept of −18.0075 (P = 0.0933, 95% CI: −39.0382 to 3.0233), with no significant covariates, though the subgroup HFrEF trended toward a positive effect (estimate: 10.3618, P = 0.1329, 95% CI: −3.1515 to 23.8752). The non-significant negative intercept (−18.0075, 95% CI: −39.0382 to 3.0233) in model 1 represents the estimated baseline log(RR) when covariates are zero (not directly clinically interpretable due to covariate centering/scaling and model extrapolation) but suggests a potential favoring of vericiguat before adjustments; wide CIs reflect uncertainty from model complexity and data limitations.Table 3Meta-regression analysis of five models summary data table for the primary outcome (hospitalization for heart failure).Model 1ParameterEstimateSEZvalPvalLower CIUpper CIIntercept−18.007510.7302−1.67820.0933−39.03823.0233Age−0.01220.0608−0.20040.8412−0.13120.1069Population−0.00030.0002−1.43710.1507−0.00070.0001Sex Female %41.131724.78581.65950.097−7.447689.711Subgroup HFrEF10.36186.89471.50290.1329−3.151523.8752Model 2ParameterEstimateSEZvalPvalLower CIUpper CIintrcpt−2.88754.9599−0.58220.5605−12.60886.8338Age0.0150.08620.17380.862−0.1540.184Population0.00.00010.11550.908−0.00020.0002Sex Female %0.05170.04471.15720.2472−0.03580.1392NT-proBNP0.00020.00070.2440.8072−0.00110.0015Model 3ParameterEstimateSEZvalPvalLower CIUpper CIintrcpt−28.655120.3147−1.41060.1584−68.471211.1609Age0.42240.28921.46090.144−0.14430.9892NT-proBNP0.00970.00811.19350.2327−0.00620.0256Age: NT-proBNP−0.00010.0001−1.2360.2165−0.00040.0001Model 4ParameterEstimateSEZvalPvalLower CIUpper CIintrcpt−1.32953.4285−0.38780.6982−8.04935.3902Sex Female %0.02610.10990.23740.8123−0.18930.2415NT-proBNP−0.00030.0017−0.14720.883−0.00370.0032Sex Female %: NT-proBNP0.00.00010.29280.7697−0.00010.0001Model 5ParameterEstimateSEZvalPvalLower CIUpper CIintrcpt−4.51373.8312−1.17810.2387−12.02282.9954Population0.00850.00551.53940.1237−0.00230.0193NT-proBNP0.00150.00141.08540.2778−0.00120.0042Population:NT-proBNP−0.00.0−1.53290.1253−0.00.0 Table 3Meta-regression analysis of five models summary data table for the primary outcome (hospitalization for heart failure).Model 1ParameterEstimateSEZvalPvalLower CIUpper CIIntercept−18.007510.7302−1.67820.0933−39.03823.0233Age−0.01220.0608−0.20040.8412−0.13120.1069Population−0.00030.0002−1.43710.1507−0.00070.0001Sex Female %41.131724.78581.65950.097−7.447689.711Subgroup HFrEF10.36186.89471.50290.1329−3.151523.8752Model 2ParameterEstimateSEZvalPvalLower CIUpper CIintrcpt−2.88754.9599−0.58220.5605−12.60886.8338Age0.0150.08620.17380.862−0.1540.184Population0.00.00010.11550.908−0.00020.0002Sex Female %0.05170.04471.15720.2472−0.03580.1392NT-proBNP0.00020.00070.2440.8072−0.00110.0015Model 3ParameterEstimateSEZvalPvalLower CIUpper CIintrcpt−28.655120.3147−1.41060.1584−68.471211.1609Age0.42240.28921.46090.144−0.14430.9892NT-proBNP0.00970.00811.19350.2327−0.00620.0256Age: NT-proBNP−0.00010.0001−1.2360.2165−0.00040.0001Model 4ParameterEstimateSEZvalPvalLower CIUpper CIintrcpt−1.32953.4285−0.38780.6982−8.04935.3902Sex Female %0.02610.10990.23740.8123−0.18930.2415NT-proBNP−0.00030.0017−0.14720.883−0.00370.0032Sex Female %: NT-proBNP0.00.00010.29280.7697−0.00010.0001Model 5ParameterEstimateSEZvalPvalLower CIUpper CIintrcpt−4.51373.8312−1.17810.2387−12.02282.9954Population0.00850.00551.53940.1237−0.00230.0193NT-proBNP0.00150.00141.08540.2778−0.00120.0042Population:NT-proBNP−0.00.0−1.53290.1253−0.00.0 Meta-regression analysis of five models summary data table for the primary outcome (hospitalization for heart failure). Model 2, adding NT-proBNP, yielded a non-significant intercept of −2.8875 (P = 0.5605, 95% CI: −12.6088 to 6.8338), with all covariates remaining non-significant, including NT-proBNP (estimate: 0.0002, P = 0.8072, 95% CI: −0.0011 to 0.0015). Model 3, focusing on age and NT-proBNP with an interaction term, reported a non-significant intercept of −28.6551 (P = 0.1584, 95% CI: −68.4712 to 11.1609), with age showing a trend toward significance (estimate: 0.4224, P = 0.144, 95% CI: −0.1443 to 0.9892). Model 4, including sex and NT-proBNP with an interaction, had a non-significant intercept of −1.3295 (P = 0.6982, 95% CI: −8.0493 to 5.3902), with no significant effects. Model 5, combining population and NT-proBNP with an interaction, showed a non-significant intercept of −4.5137 (P = 0.2387, 95% CI: −12.0228 to 2.9954), with population trending toward significance (estimate: 0.0085, P = 0.1237, 95% CI: −0.0023 to 0.0193). Figure 6B illustrates the regression coefficients, highlighting the dominant influence of the intercept and subgroup HFrEF, whereas Figure 6C presents a bubble plot showing a clustered effect size distribution with varying weights, suggesting heterogeneity in the impact of vericiguat across HF phenotypes, warranting further exploration to refine treatment strategies. Discussion This meta-analytic study provides a comprehensive assessment of Vericiguat’s effectiveness across HF phenotypes, synthesizing data from 17,381 patients across eight RCTs. By focusing on key outcomes – hospitalization for HF, all-cause mortality, cardiovascular mortality, and the composite endpoint of cardiovascular death or first hospitalization – this analysis addresses critical gaps in prior research through the novel application of TSA, meta-regression, and advanced sensitivity analyses (Table 4). The findings offer nuanced insights into Vericiguat’s therapeutic potential, particularly in HFrEF, while highlighting areas of uncertainty in HFpEF, with implications for clinical practice and future research in the context of evolving HF management strategies. Risk stratification tools like GRACE and TIMI, validated in precursor conditions such as acute coronary syndromes, could complement Vericiguat therapy by identifying patients at highest risk for decompensation, potentially enhancing its targeted use in high-risk HF subgroups.Table 4Summary table listing assumptions (effect size, alpha, power, required information size) for each TSA analysis.OutcomeEffect Size (RR)95% CIAlphaPowerRequired information sizeHospitalization for heart failure0.90[0.82, 0.98]0.050.8029,929All-cause mortality0.98[0.68, 1.40]0.050.806678Cardiovascular mortality0.91[0.64, 1.30]0.050.80184,229Primary composite outcome0.88[0.78, 0.99]0.050.8048,016 Table 4Summary table listing assumptions (effect size, alpha, power, required information size) for each TSA analysis.OutcomeEffect Size (RR)95% CIAlphaPowerRequired information sizeHospitalization for heart failure0.90[0.82, 0.98]0.050.8029,929All-cause mortality0.98[0.68, 1.40]0.050.806678Cardiovascular mortality0.91[0.64, 1.30]0.050.80184,229Primary composite outcome0.88[0.78, 0.99]0.050.8048,016 Summary table listing assumptions (effect size, alpha, power, required information size) for each TSA analysis. Effectiveness on hospitalization and composite outcomes The pooled RR for hospitalization for HF (RR: 0.90, 95% CI: 0.82–0.98, P = 0.0201) indicates a modest benefit of Vericiguat, consistent with the VICTORIA trial’s findings in HFrEF patients (hazard ratio: 0.90, 95% CI: 0.82–0.98, P = 0.02)[10]. However, the TSA revealed that the required information size of 29,929 patients was not met, suggesting that this benefit remains inconclusive[15]. This “required information size not met” in TSA means the cumulative evidence is insufficient to reliably confirm or refute the effect, reducing the risk of premature conclusions from underpowered data. Similarly, the primary composite outcome of cardiovascular death or first hospitalization showed a statistically significant reduction (RR: 0.88, 95% CI: 0.78–0.99, P = 0.035), but the TSA highlighted an unmet information size of 48,016 patients, indicating the need for further trials to confirm this effect[16]. These findings align with the challenges of establishing robust evidence in HFpEF, as noted in prior meta-analyses where sample sizes often limit definitive conclusions[13]. The modest effect on hospitalization supports Vericiguat’s role in reducing hemodynamic burden through the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate pathway, which enhances vasodilation and reduces cardiac stress[9]. This mechanism is particularly relevant for HFrEF patients with recent decompensation, a group prioritized in recent guidelines for targeted therapies[22]. Lack of mortality benefit The absence of a significant effect on all-cause mortality (RR: 0.98, 95% CI: 0.68–1.40, P = 0.904) and cardiovascular mortality (RR: 0.91, 95% CI: 0.64–1.30, P = 0.6091) is a critical finding. The TSA confirmed insufficient power to detect a mortality benefit, with cumulative Z-curves remaining near the null for both outcomes[21]. This lack of effect contrasts with other HF therapies, such as SGLT2 inhibitors, which have demonstrated mortality reductions across HFrEF and HFpEF[5]. Vericiguat’s primary action on vasodilation and preload reduction may not directly address the multifactorial causes of mortality in HF, such as arrhythmic events or progressive pump failure, which are more prevalent in advanced disease[3]. Recent studies suggest that sGC stimulators may exert greater benefits on quality of life and functional outcomes rather than survival, a hypothesis that warrants further exploration[28]. The 2023 European Society of Cardiology Guidelines for HF management also note that while Vericiguat is recommended for HFrEF patients with worsening symptoms, its impact on mortality remains unproven, supporting our findings[29]. Demographic and phenotypic variability The baseline characteristics of the included studies highlight significant demographic variability, with HFrEF cohorts showing a lower proportion of female participants (19.7–24.1%) compared to HFpEF (46.6–49%). This aligns with the known epidemiology of HF, where HFpEF is more prevalent in older females due to factors like diastolic dysfunction and systemic inflammation[6]. The mean age range of 67.3–73 years across studies reflects the typical HF population, but the higher female representation in HFpEF trials suggests potential sex-specific responses to Vericiguat that were not fully explored in this analysis[30]. The meta-regression analysis (see Sensitivity analysis: influence diagnostics of the meta-regression model section) found no significant covariate effects of age, sex, or NT-proBNP levels on Vericiguat’s efficacy, though a trend toward a positive effect in HFrEF subgroups (model 1: estimate 10.3618, P = 0.1329) suggests phenotype-specific differences[27]. This variability underscores the importance of tailoring HF therapies to specific phenotypes, a principle emphasized in the 2022 AHA/ACC/HFSA Guidelines[31]. Importantly, low statistical heterogeneity (I2 = 0–17%) does not preclude substantial clinical heterogeneity between HFrEF and HFpEF, including distinct pathophysiologies (systolic vs. diastolic dysfunction, inflammation predominance in HFpEF), demographic profiles (higher female prevalence and older age in HFpEF), and differential treatment responses. Our HFrEF-restricted sensitivity analysis (see Sensitivity analysis in heart failure with reduced ejection fraction section) helps isolate more robust effects in the better-evidenced phenotype, while the overall mixed results likely reflect this clinical diversity. Statistical rigor and novel methodologies The use of TSA to control for type I and type II errors is a significant advancement over prior Vericiguat meta-analyses, which often failed to assess the reliability of cumulative evidence[13]. TSA’s application ensured that conclusions were not drawn prematurely, a concern in meta-analyses with variable trial sizes (6678–16,866 patients across outcomes)[15]. The meta-regression analysis, previously unapplied in Vericiguat studies, provided insights into potential effect modifiers, although the non-significant results (e.g., NT-proBNP: estimate 0.0002, P = 0.8072) may reflect limited statistical power or unmeasured confounders[17]. The sensitivity analysis identified the VITALITY-HFpEF trial as a significant outlier (r-student: 3.1048, Cook’s distance: 0.5938), likely due to its focus on HFpEF, where Vericiguat’s efficacy remains less established[11]. This finding highlights the heterogeneity between HFrEF and HFpEF, consistent with recent literature advocating for phenotype-specific analyses in HF research[32]. The large required information sizes identified by TSA – for hospitalization (29,929 patients; current cumulative n = 16,866, gap ≈ 11,243 patients) and composite outcome (48,016 patients; current n = 16,685, gap ≈ 31,331 patients) – indicate that existing evidence, while suggestive of modest benefits, remains underpowered to definitively confirm or refute effects with adequate control for random error. Clinically, these gaps highlight practical challenges: confirming modest RR reductions (e.g., 10–12%) in HF requires large, resource-intensive, multinational trials, particularly in underrepresented HFpEF populations. Until these sizes are met, clinicians should interpret Vericiguat’s benefits cautiously as hypothesis-generating, prioritizing established therapies while awaiting confirmatory data. Clinical implications The modest reduction in hospitalization and composite outcomes supports Vericiguat’s role as an adjunctive therapy in HFrEF, particularly for patients with recent worsening events, as recommended by the 2022 AHA/ACC/HFSA Guidelines[31]. However, its lack of mortality benefit suggests that it should not replace cornerstone therapies like SGLT2 inhibitors or ARNIs, which have broader survival benefits[5]. In HFpEF, the inconclusive findings (e.g., VITALITY-HFpEF’s limited impact on functional outcomes) indicate a need for further research, as HFpEF remains a therapeutic challenge with fewer evidence-based options[6]. Clinicians should consider Vericiguat in HFrEF patients with persistent symptoms despite optimal medical therapy, but its role in HFpEF requires cautious interpretation pending more robust data[29]. Future research directions The unmet information sizes identified by TSA for all outcomes underscore the need for larger RCTs to achieve conclusive evidence, particularly in HFpEF, where trial data are sparse[16]. Future studies should prioritize diverse populations to address demographic variability, such as the higher female prevalence in HFpEF, which may influence treatment response[30]. The trend toward significance in HFrEF subgroups in the meta-regression suggests that phenotype-specific trials could clarify Vericiguat’s differential effects[27]. Additionally, exploring biomarkers like NT-proBNP in greater detail, as suggested by recent studies on biomarker-guided HF therapy, could identify patients most likely to benefit from Vericiguat[33]. The integration of advanced statistical methods, such as Bayesian meta-analysis, could further enhance the precision of effect estimates, a methodology gaining traction in cardiovascular research[34]. Finally, longitudinal studies assessing Vericiguat’s impact on quality of life, healthcare costs, and long-term outcomes, as recommended by the 2023 ISPOR guidelines, would provide a more comprehensive understanding of its clinical utility[35]. Regarding Vericiguat’s safety, common adverse reactions include hypotension, anemia, and headache, with a toxicity profile involving potential embryo-fetal harm (contraindicated in pregnancy); other contraindications include concomitant use with PDE-5 inhibitors and severe hepatic impairment, as these may exacerbate hypotensive effects or alter metabolism. Limitations This study has several limitations. The small number of included HFpEF trials (only three) limits generalizability to this phenotype, potentially underrepresenting its unique challenges. The predominance of HFrEF trials (e.g., P. W. Armstrong et al., 2020, 2022) may skew results toward this phenotype, potentially underrepresenting HFpEF’s unique challenges[8,12]. The strong influence of the VITALITY-HFpEF trial indicates single-study dominance, which could bias HFpEF-specific interpretations. The meta-regression’s non-significant findings may reflect unmeasured confounders, such as comorbidities or ethnicity, which were not consistently reported across studies[17]. Additionally, the lack of patient-level data in the meta-regression restricts the ability to explore individualized effects or interactions more granularly. Furthermore, the influence of the VITALITY-HFpEF trial suggests potential bias in HFpEF-specific outcomes, necessitating cautious interpretation[11]. Moreover, while statistical heterogeneity was minimal, clinical heterogeneity between HFrEF and HFpEF phenotypes (e.g., differing pathophysiology, demographics, and comorbidity profiles) may not be fully captured by I2 alone, potentially influencing generalizability despite our sensitivity and subgroup approaches. Conclusion This meta-analysis demonstrates that Vericiguat offers a modest benefit in reducing hospitalization and composite outcomes in HF, particularly in HFrEF, but its effects on mortality remain inconclusive. The novel application of TSA and meta-regression highlights the need for larger, phenotype-specific trials to confirm Vericiguat’s efficacy, especially in HFpEF. These findings provide a foundation for optimizing Vericiguat’s role in clinical practice while underscoring the importance of continued research to address the unmet needs of diverse HF populations.